Brief: Homology Medicines Announces Encouraging Initial Data From First Dose Level In The PheEDIT Trial

Q32 Bio

27/07/2023 22:58

July 27 (Reuters) - Homology Medicines Inc  FIXX.O :
    * HOMOLOGY MEDICINES ANNOUNCES ENCOURAGING INITIAL DATA FROM
FIRST
DOSE LEVEL IN THE PHEEDIT TRIAL EVALUATING GENE EDITING
CANDIDATE HMI-103 IN ADULTS WITH CLASSICAL PKU
    * HOMOLOGY MEDICINES INC: HMI-103 HAS BEEN GENERALLY
WELL-TOLERATED
    * HOMOLOGY MEDICINES INC: PARTICIPANT 2 PLASMA PHE LEVEL
REDUCTION
OF 49% CHANGE FROM BASELINE AT 17 WEEKS POST-DOSE

Source text for Eikon:  ID:nGNX2snFLP 
Further company coverage:  FIXX.O 

 (Reuters.Briefs@thomsonreuters.com)